Results 1 to 10 of about 12,240 (169)

Micafungin Inhibits Dengue Virus Infection through the Disruption of Virus Binding, Entry, and Stability

Pharmaceuticals, 2021
Dengue fever is an arbovirus disease caused by infection with the dengue virus (DENV). Half of the world’s population lives under the threat of dengue fever, however, researchers have yet to develop any drugs that are clinically applicable to this ...
彥禎 陳, Jeng-Wei Lu, Feng-Cheng Liu
exaly   +4 more sources

Antiviral Activity of Micafungin and Its Derivatives against SARS-CoV-2 RNA Replication

Viruses, 2023
Echinocandin antifungal drugs, including micafungin, anidulafungin, and caspofungin, have been recently reported to exhibit antiviral effects against various viruses such as flavivirus, alphavirus, and coronavirus. In this study, we focused on micafungin
Shogo Nakajima, Hirofumi Ohashi, Daisuke Akazawa, Shiho Torii, Rigel Suzuki, Takasuke Fukuhara, Koichi Watashi   +6 more
doaj   +2 more sources

In vitro interactions of nystatin and micafungin combined with chlorhexidine against Candida albicans isolates [PDF]

Current Medical Mycology, 2022
Background and Purpose: Oral candidiasis has become a growing problem in hospitals worldwide, and the development of antifungal drug resistance in Candida species constitutes a serious concern.
Maede Salehi, Ali Malekzadeh Shafaroudi, Maryam Daryani, Alireza Khalilian, Fatemeh Ahangarkani, Tahere Molania   +5 more
doaj   +2 more sources

Plasma and Cerebrospinal Fluid Concentrations of Micafungin Administered at High Doses in Critically Ill Infants with Systemic Candidiasis: A Pooled Analysis of Two Studies

Pharmaceuticals, 2023
Background: Neonates may require higher doses of micafungin than adults to reach the therapeutic effect for increased plasma clearance. Only poor and inconclusive data are available still now to support this hypothesis, especially with regard to central ...
Domenico Umberto De Rose, Iliana Bersani, Maria Paola Ronchetti, Fiammetta Piersigilli, Sara Cairoli, Andrea Dotta, Amit Desai, Laura Lynn Kovanda, Bianca Maria Goffredo, Cinzia Auriti   +9 more
doaj   +2 more sources

Characterizing Safety and Clinical Outcomes Associated with High-Dose Micafungin Utilization in Patients with Proven Invasive Candidiasis

Tropical Medicine and Infectious Disease, 2022
Micafungin is the empiric antifungal agent of choice for the treatment of invasive candidiasis (IC). Pathophysiologic changes that occur in obese and/or critically ill patients can alter micafungin serum concentrations and the probability of target ...
Victoria C. Grant, Kenneth Nguyen, Sasha Rodriguez, Anna Y. Zhou, Jacinda C. Abdul-Mutakabbir, Karen K. Tan   +5 more
doaj   +2 more sources

Species Distribution of Candidemia and Their Susceptibility in a Single Japanese University Hospital: Prior Micafungin Use Affects the Appearance of Candida parapsilosis and Elevation of Micafungin MICs in Non-parapsilosis Candida Species

Journal of Fungi, 2021
Introduction: Micafungin is a recommended echinocandin antifungal agent for candidemia treatment and prophylaxis. However, overuse of echinocandin antifungals may cause resistance.
Yasutaka Sakamoto, Kazuhiro Kawabe, Tomoyo Suzuki, Kayoko Sano, Kazuo Ide, Tetsuta Nishigaki, Yuki Enoki, Kazuaki Taguchi, Hirofumi Koike, Hideaki Kato, Yukiko Sahashi, Kazuaki Matsumoto   +11 more
doaj   +2 more sources

A case of bloodstream co-infection of Saccharomyces cerevisiae and Candida glabrata while using micafungin

BMC Infectious Diseases, 2023
Background Saccharomyces cerevisiae is ubiquitous in the gastrointestinal tract and known as brewer's or baker's yeast. We experienced a case of S. cerevisiae and Candida glabrata co-infectious bloodstream infection.
Kento Furuya, Kenta Ito, Kyohei Sugiyama, Satoshi Tokuda, Hideyuki Kanemoto, Katsuhiko Kamei, Toshio Shimada   +6 more
doaj   +2 more sources

Assessment of Micafungin Dosage Regimens in Patients with Cancer Using Pharmacokinetic/Pharmacodynamic Modeling and Monte Carlo Simulation

Antibiotics, 2021
Micafungin is widely used for invasive candidiasis, especially in critically ill patients and those with cancer, and for empirical antifungal therapy in patients with neutropenic fever.
Saeed Alqahtani, Asma Alfarhan, Abdullah Alsultan, Emad Alsarhani, Abdulaziz Alsubaie, Yousif Asiri   +5 more
doaj   +2 more sources

Does DHN-Melanin Always Protect Fungi against Antifungal Drugs? The Fonsecaea/Micafungin Paradigm

Microbiology Research, 2022
Several human pathogenic fungi produce melanin. One of its properties during parasitism is the protection against antifungal drugs. This occurs with the agents of chromoblastomycosis, in which DHN-melanin reduces antifungal susceptibility to terbinafine ...
Rowena Alves Coelho, Maria Helena Galdino Figueiredo-Carvalho, Juliana Vitória dos Santos Silva, Dario Correa-Junior, Susana Frases, Rosely Maria Zancopé-Oliveira, Dayvison Francis Saraiva Freitas, Rodrigo Almeida-Paes   +7 more
doaj   +2 more sources

Combination of Systemic and Lock-Therapies with Micafungin Eradicate Catheter-Based Biofilms and Infections Caused by Candida albicans and Candida parapsilosis in Neutropenic Rabbit Models

Journal of Fungi
Vascular catheter-related infections, primarily caused by Candida albicans and Candida parapsilosis, pose significant challenges due to the formation of biofilms on catheters, leading to refractory disease and considerable morbidity.
Ruta Petraitiene, Vidmantas Petraitis, Myo H. Zaw, Kaiser Hussain, Rodolfo J. Ricart Arbona, Emanuel Roilides, Thomas J. Walsh   +6 more
doaj   +2 more sources